An observational study in Gastroenteropancreatic Neuroendocrine Tumours, sponsored by Ipsen. Completed at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-02.
Sponsored by Ipsen · Observational
Data from this study will contribute additional knowledge regarding patient outcomes and direct somatostatin analogue (SSA) treatment related costs in clinical practice in the Nordic countries. Such knowledge can be of importance in a treatment decision, decision support for development of care, follow up and training of both patients and primary care nurses.
676 studies on the registry are indexed under Neuroendocrine Tumors; 169 are open to participants now.
This study's enrollment of 156 is above the median of 115 across 176 observational studies indexed under Neuroendocrine Tumors.
Browse Neuroendocrine Tumors studies →Ipsen is the lead sponsor of 282 studies on the registry; 16 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 19 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Treatment clinic
Exclusion Criteria:
Proportion of subjects with injection problems according to the subject
Subject questionnaire asks "In your opinion, how did the last injection go?", subject chooses either 'no problems' or 'problems occurred'.
Time frame: Day 1
Quality of life, mean physical health score in SF-12 derived according to the SF-12 manual.
Mean physical health score and mean mental health score in SF-12 derived according to the SF-12 manual
Time frame: Day 1
Quality of life, mean mental health score in SF-12 derived according to the SF-12 manual.
Time frame: Day 1
Subject experience: proportion of subjects reporting "much" or "very much" anxiety in subject questionnaire.
Subjects asked "To what extent do you feel anxiety before the injection?"
Time frame: Day 1
Mean number of packs of H01CB03 and H01CB02 purchased.
Time frame: Retrospective data collection of a 1 year period
Median number of packs of H01CB03 and H01CB02 purchased.
Time frame: Retrospective data collection of a 1 year period
Mean number of two consecutive dispensed prescriptions of H01CB03, H01CB02 within seven days during the pre-specified one-year period of retrospective data extraction.
Time frame: Retrospective data collection of a 1 year period
Median number of two consecutive dispensed prescriptions of H01CB03, H01CB02 within seven days during the pre-specified one-year period of retrospective data extraction.
Time frame: Retrospective data collection of a 1 year period
Median frequency of visits to treating physician in hospital will be derived as number of (frequency) of revisits recorded in the subject questionnaire.
Time frame: Day 1
Median time - visits to primary care for injections; visits to treating physician at hospital; time to travel
Time frame: Day 1
Median time for giving injections of SSA in subjects, derived as the time reported in the nurse questionnaire.
Time frame: Day 1
Proportion of nurses who reported "moderately" or "very" or "very much" confidence in giving injections
Time frame: Day 1
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ipsen